Journal of Obstetrics, Gynecology and Cancer Research

Published by: Kowsar

The Effectiveness of Ferric Carboxymaltose on the Improvement of Chronic Iron Deficiency Anemia in Patients With Colon Cancer: A Controlled Randomized Clinical Trial

Authors Information
1 Department of Hematology and Oncology, Hazrat Rasool-e Akram Hospital, Iran University of Medical Sciences, Tehran, IR Iran
2 Cancer Pharmacogenetics Research Group (CPGRG), Iran University of Medical Sciences, Tehran, IR Iran
3 Department of Medical Genetic, Medical Biotechnology Ins., National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, IR Iran
4 Hospital Pharmacy Management, Iran University Medical Sciences, Tehran, IR Iran
Article Notes and Dates
Journal of Obstetrics, Gynecology and Cancer Research: August 31, 2016, 1 (2); e8006.Published Online: August 28, 2016
Article Type: Research Article; Received : July 25, 2016; Revised : August 2, 2016; Accepted : August 20, 2016
DOI: http://dx.doi.org/ 10.17795/jogcr-8006

To Cite : Ansarinejad N, Abbasi B, Sadat Rasul M S, Fardad F, Ramim T. et al. The Effectiveness of Ferric Carboxymaltose on the Improvement of Chronic Iron Deficiency Anemia in Patients With Colon Cancer: A Controlled Randomized Clinical Trial, J Obstet Gynecol Cancer Res. 2016 ;1(2):e8006. doi: 10.17795/jogcr-8006.

Abstract
Copyright: Copyright © 2016, Journal of Obstetrics, Gynecology and Cancer Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
References
  • 1. Iron deficiency anemia: assessment. 2001;
  • 2. Arora NP, Ghali JK. Iron deficiency anemia in heart failure. Heart Fail Rev. 2013; 18(4): 485-501[DOI][PubMed]
  • 3. Goddard AF, James MW, McIntyre AS, Scott BB, British Society of G. Guidelines for the management of iron deficiency anaemia. Gut. 2011; 60(10): 1309-16[DOI][PubMed]
  • 4. Breymann C, Bian XM, Blanco-Capito LR, Chong C, Mahmud G, Rehman R. Expert recommendations for the diagnosis and treatment of iron-deficiency anemia during pregnancy and the postpartum period in the Asia-Pacific region. J Perinat Med. 2011; 39(2): 113-21[DOI][PubMed]
  • 5. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoiesis (CME). Transfusion. 2012; 52(7): 1584-92[DOI][PubMed]
  • 6. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum. 1997; 40(1): 15-24[PubMed]
  • 7. Ganz T. Systemic iron homeostasis. Physiol Rev. 2013; 93(4): 1721-41[DOI][PubMed]
  • 8. Hedenus M, Karlsson T, Ludwig H, Rzychon B, Felder M, Roubert B, et al. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med Oncol. 2014; 31(12): 302[DOI][PubMed]
  • 9. Geisser P. The pharmacology and safety profile of ferric carboxymaltose (Ferinject): structure/reactivity relationships of iron preparation. Port J Nephrol Hypert. 2009; 23(1): 11-6
  • 10. Funk F, Ryle P, Canclini C, Neiser S, Geisser P. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung. 2010; 60(6a): 345-53[DOI][PubMed]
  • 11. Geisser P, Rumyantsev V. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder. Arzneimittelforschung. 2010; 60(6a): 373-85[DOI][PubMed]
  • 12. Geisser P, Banke-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittelforschung. 2010; 60(6a): 362-72[DOI][PubMed]
  • 13. Bisbe E, Molto L, Arroyo R, Muniesa JM, Tejero M. Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty. Br J Anaesth. 2014; 113(3): 402-9[DOI][PubMed]
  • 14. clinical practice guidelines in oncology (NCCN guidelines). Cancer and chemotheraphy induced anemia. 2015;
  • 15. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361(25): 2436-48[DOI][PubMed]
  • 16. Borstlap WA, Buskens CJ, Tytgat KM, Tuynman JB, Consten EC, Tolboom RC, et al. Multicentre randomized controlled trial comparing ferric(III)carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients. BMC Surg. 2015; 15: 78[DOI][PubMed]
  • 17. Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013; 24(2): 475-82[DOI][PubMed]
  • 18. Toledano A, Luporsi E, Morere JF, Scotte F, Huot-Marchand P, Zakin L, et al. Observational study of ferric carboxymaltose (FCM) in france (oncofer study; interim analysis). Value Health. 2013; 16(3)
  • 19. Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol. 2013; 131(3): 679-82[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Cited By:

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader